<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03389555</url>
  </required_header>
  <id_info>
    <org_study_id>2017P000436</org_study_id>
    <nct_id>NCT03389555</nct_id>
  </id_info>
  <brief_title>Ascorbic Acid, Corticosteroids, and Thiamine in Sepsis (ACTS) Trial</brief_title>
  <official_title>Ascorbic Ccid, Hydrocortisone, and Thiamine in Sepsis and Septic Shock - A Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Open Philanthropy Project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, we aim to determine whether the combination of Ascorbic Acid (Vitamin C),
      Thiamine (Vitamin B1), and Corticosteroids improves the trajectory of organ failure and
      reduces mortality in patients with sepsis and septic shock as compared to placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sepsis and Septic Shock are common and highly morbid clinical conditions without any specific
      therapy aside from antibiotics. A recent quasi-experimental study (Marik et. al., PMID
      27940189) demonstrated a remarkable benefit when the combination of Ascorbic Acid (Vitamin
      C), Corticosteroids, and Thiamine (Vitamin B1) were given to patients with sepsis. In
      particular, patients who received this combination of medications required a shorter amount
      of time on vasopressors, suffered less organ failure, and had improved mortality. Vitamin C
      has long been suggested for treatment of patients with severe infection as it exerts
      significant anti-oxidant effects and reduces endothelial permeability. Corticosteroids, a
      mainstay of therapy for refractory shock in sepsis, have also been shown to enhance the
      beneficial cellular effects of vitamin C. Finally, thiamine has been shown to be an effective
      mitochondrial resuscitator in sepsis, especially for the ~30% of septic shock patients who
      present with thiamine deficiency (Donnino et. al, PMID 26771781).

      In this study, we aim to reproduce the findings of Marik et. al. using a more rigorous study
      design (i.e. a blinded, randomized clinical trial) and focus on the important clinical
      outcomes of organ failure and death.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sequential Organ Failure Assessment (SOFA) Score Change</measure>
    <time_frame>Enrollment to 72-hours</time_frame>
    <description>Change in degree of organ dysfunction as defined by the Sequential Organ Failure Assessment (SOFA) Score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal Failure</measure>
    <time_frame>Enrollment until discharge from the ICU</time_frame>
    <description>Development of renal failure as defined by a Kidney Disease Improving Global Outcomes [KDIGO] grade 3 or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>Enrollment until 30-days after enrollment</time_frame>
    <description>Mortality rate</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Ventilator free days</measure>
    <time_frame>Ventilator free days over the first 7-days after enrollment</time_frame>
    <description>Days not receiving invasive mechanical ventilation</description>
  </other_outcome>
  <other_outcome>
    <measure>Vasopressor free days</measure>
    <time_frame>Vasopressor free days over the first 7-days after enrollment</time_frame>
    <description>Days not receiving vasopressor</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>Enrollment until ICU discharge</time_frame>
    <description>Number of days in the ICU during the index ICU admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of Hospital stay</measure>
    <time_frame>Enrollment until hospital discharge</time_frame>
    <description>Number of days in the hospital during the index hospital admission</description>
  </other_outcome>
  <other_outcome>
    <measure>Delirium</measure>
    <time_frame>Day 3 of hospital stay</time_frame>
    <description>Incidence of delirium</description>
  </other_outcome>
  <other_outcome>
    <measure>Quality of life</measure>
    <time_frame>90-days after enrollment</time_frame>
    <description>Quality of life as assessed by the SF-36 quality-of-life survey</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Sepsis</condition>
  <condition>Septic Shock</condition>
  <condition>Metabolic Disturbance</condition>
  <arm_group>
    <arm_group_label>Vitamin C, Vitamin B1, Corticosteroids</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The combination of vitamin C, vitamin B1, hydrocortisone :
Vitamin C (ascorbic acid) 1.5g every 6 hours x 4-days
Vitamin B1 (thiamine) 100mg every 6 hours x 4-days
Hydrocortisone 50mg every 6 hours x 4-days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline Solution (0.9%NaCl) in a volume to match all experimental arm components</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vitamin C, vitamin B1, hydrocortisone</intervention_name>
    <description>Vitamin C (1.5g) plus vitamin B1 (100mg) will be diluted in 100ml 0.9%NACL and administered IV every 6 hours for 4 days or until participant is discharged from the ICU. Hydrocortisone 50mg/ml will be administered via IV push over 1-2 minutes every 6hours for 4 days or until the patient is discharged from the ICU.</description>
    <arm_group_label>Vitamin C, Vitamin B1, Corticosteroids</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
    <other_name>Thiamine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>Normal saline (0.9% NaCl solution) volume to match all components</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patient (age ≥ 18 years)

          2. Suspected (cultures drawn and antibiotic given) or confirmed (via culture results)
             infection

          3. Receiving vasopressor (norepinephrine, phenylephrine, epinephrine, dopamine, or
             vasopressin)

        Exclusion Criteria:

          1. Member of a protected population (pregnant, prisoner)

          2. Known kidney stones within the past 1 year

          3. Chronic kidney disease (CKD stage ≥3b and above)

          4. Known Glucose-6-Phosphate Dehydrogenase deficiency

          5. Known Hemachromatosis

          6. Comfort Measures Only status

          7. Anticipated death within 24-hours despite maximal therapy (as determined by the
             enrolling physician)

          8. Receiving supplemental thiamine in a dose greater than that contained in a
             multivitamin

          9. Clinical indication for steroids (e.g. chronic use) as determined by the clinical team
             providing this drug

         10. Clinical indication for thiamine as determined by the clinical team providing this
             drug

         11. Known allergy to vitamin C, hydrocortisone, or thiamine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael W Donnino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael W. Donnino, MD</last_name>
    <phone>617-754-2341</phone>
    <email>mdonnino@bidmc.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Derek P. Guanaga</last_name>
    <phone>617-754-2881</phone>
    <email>dguanaga@bidmc.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic - Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayan Sen, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Hou, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ari Moskowitz, MD</last_name>
      <phone>617-754-3464</phone>
      <email>amoskowitz@bidmc.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Derek P Guanaga</last_name>
      <phone>617-754-2881</phone>
      <email>dguanaga@bidmc.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael W Donnino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Auburn Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jessica McCannon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Sherwin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Sherwin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno DiGiovine, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sinai Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Sherwin, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Otero, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Gong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Long Island Jewish Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Gong, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas Health Science Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pratik Doshi, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Marik PE, Khangoora V, Rivera R, Hooper MH, Catravas J. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017 Jun;151(6):1229-1238. doi: 10.1016/j.chest.2016.11.036. Epub 2016 Dec 6.</citation>
    <PMID>27940189</PMID>
  </reference>
  <reference>
    <citation>Moskowitz A, Andersen LW, Cocchi MN, Karlsson M, Patel PV, Donnino MW. Thiamine as a Renal Protective Agent in Septic Shock. A Secondary Analysis of a Randomized, Double-Blind, Placebo-controlled Trial. Ann Am Thorac Soc. 2017 May;14(5):737-741. doi: 10.1513/AnnalsATS.201608-656BC.</citation>
    <PMID>28207287</PMID>
  </reference>
  <reference>
    <citation>Donnino MW, Andersen LW, Chase M, Berg KM, Tidswell M, Giberson T, Wolfe R, Moskowitz A, Smithline H, Ngo L, Cocchi MN; Center for Resuscitation Science Research Group. Randomized, Double-Blind, Placebo-Controlled Trial of Thiamine as a Metabolic Resuscitator in Septic Shock: A Pilot Study. Crit Care Med. 2016 Feb;44(2):360-7. doi: 10.1097/CCM.0000000000001572.</citation>
    <PMID>26771781</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 27, 2017</study_first_submitted>
  <study_first_submitted_qc>January 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2018</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Michael Donnino</investigator_full_name>
    <investigator_title>Associate Professor of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Sepsis</keyword>
  <keyword>Metabolic Resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Thiamine</mesh_term>
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
    <mesh_term>Vitamin B Complex</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

